Sermorelin
$GHRH analog with established pharmacology; Off-label wellness use varies
Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone. It stimulates the pituitary to release growth hormone, so it requires a responsive pituitary rather than bypassing the axis like direct hGH.
The pharmacology is well understood, but many wellness claims exceed the evidence. Because the peptide half-life is very short, benefits depend on downstream GH pulsatility and IGF-1 response, not on maintaining high sermorelin levels. Don't expect immediate body-composition changes from a short half-life alone.
Evaluate IGF-1, sleep, glucose, edema, and whether symptoms match true GH deficiency versus general aging complaints.
Classification details
- Sermorelin is not among the peptides affected by the 2023 Category 2 action or the 2026 reclassification.
- It has its own FDA-approval history (1997) for pediatric GH deficiency and has never been on the restricted list, which is a meaningful differentiator for clinicians seeking a regulatorily-settled GHRH analog.
- Sermorelin is a synthetic 29-amino acid peptide that represents the amino-terminal fragment of the naturally occurring human Growth Hormone-Releasing Hormone (GHRH).
- While natural GHRH is 44 amino acids long, researchers in the 1970s discovered that the first 29 amino acids contain the full biological potency.
- It is classified as a Growth Hormone Secretagogue (GHS) and was the first GHRH analog to be FDA-approved (though the brand name Geref was discontinued in 2008 for commercial reasons).
- Sermorelin is GHRH(1-29), a short-acting GHRH analog historically used in GH-axis testing/therapy contexts. It is distinct from CJC-DAC and ghrelin mimetics.
The Pituitary Stimulator Unlike GHRPs (like Ipamorelin) which mimic ghrelin, Sermorelin acts directly on the GHRH receptors:
- Direct Receptor Binding: It binds to the GHRH receptors in the anterior pituitary, stimulating the production and secretion of endogenous Growth Hormone.
- Preservation of Feedback Loops: Because it stimulates the pituitary rather than replacing GH (like synthetic HGH does), the body’s natural somatostatin feedback loop remains intact. This prevents “GH bleed” and reduces the risk of excessive hormone levels.
- Physiological Pulsatility: Sermorelin mimics the natural, pulsatile release of GH, which is essential for maintaining youthful metabolic function and avoiding receptor desensitization.
- Transcription Enhancement: It encourages the pituitary gland to increase the transcription of GH messenger RNA (mRNA), essentially “strengthening” the pituitary’s ability to produce its own hormones over time.
- It stimulates pituitary GHRH receptors, relying on pituitary capacity to release endogenous GH. It does not bypass the axis like exogenous GH.